UF expert answers questions about the newly approved RSV vaccine
On May 3, the U.S. Food and Drug Administration approved a vaccine manufactured by GlaxoSmithKline to prevent respiratory syncytial virus, or RSV, in older adults. In clinical trials, the vaccine, called Arexvy, was 83% effective at preventing lower respiratory tract disease in older adults and 94% effective at preventing severe…